Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 22 of 22 results for baricitinib

  1. Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    11 October 2017
    View recommendations

    Sections for TA480

  2. Baricitinib for moderate to severe rheumatoid arthritis (TA466)

    Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    9 August 2017
    View recommendations

    Sections for TA466

  3. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued [GID-TA10892]

    Technology appraisal guidance
    Discontinued

  4. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]

    In development [GID-TA11066] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]

    In development [GID-TA11349] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]

    In development [GID-TA11297] Expected publication date: 08 May 2024

    Technology appraisal guidance
    In development